Fox Run Management L.L.C. purchased a new position in shares of Mallinckrodt PLC (NYSE:MNK) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 47,179 shares of the company’s stock, valued at approximately $1,064,000.
A number of other large investors also recently bought and sold shares of MNK. HealthCor Management L.P. purchased a new position in Mallinckrodt during the second quarter worth approximately $107,649,000. Janus Henderson Group PLC increased its position in shares of Mallinckrodt by 6,828.1% in the second quarter. Janus Henderson Group PLC now owns 1,396,780 shares of the company’s stock worth $62,590,000 after acquiring an additional 1,376,619 shares in the last quarter. Prudential Financial Inc. increased its position in shares of Mallinckrodt by 114.9% in the third quarter. Prudential Financial Inc. now owns 1,379,978 shares of the company’s stock worth $51,569,000 after acquiring an additional 737,791 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Mallinckrodt by 33.9% in the second quarter. Dimensional Fund Advisors LP now owns 2,161,814 shares of the company’s stock worth $96,868,000 after acquiring an additional 547,249 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its position in shares of Mallinckrodt by 45.8% in the third quarter. Alyeska Investment Group L.P. now owns 1,535,583 shares of the company’s stock worth $57,385,000 after acquiring an additional 482,591 shares in the last quarter.
Several equities research analysts have recently issued reports on MNK shares. Zacks Investment Research lowered shares of Mallinckrodt from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $52.00 price objective on shares of Mallinckrodt in a research report on Thursday, November 2nd. UBS Group set a $70.00 price objective on shares of Mallinckrodt and gave the stock a “buy” rating in a research report on Friday, October 6th. Goldman Sachs Group started coverage on shares of Mallinckrodt in a research report on Thursday, September 28th. They issued a “buy” rating and a $55.00 price objective for the company. Finally, Canaccord Genuity lowered shares of Mallinckrodt from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $77.00 to $40.00 in a research report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have given a buy rating to the company’s stock. Mallinckrodt has an average rating of “Hold” and an average target price of $44.99.
Shares of Mallinckrodt PLC (MNK) opened at $21.70 on Friday. The firm has a market cap of $2,116.71, a price-to-earnings ratio of 5.86, a P/E/G ratio of 0.42 and a beta of 1.30. Mallinckrodt PLC has a fifty-two week low of $19.00 and a fifty-two week high of $55.32. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 1.08.
Mallinckrodt (NYSE:MNK) last released its quarterly earnings results on Tuesday, November 7th. The company reported $1.97 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.17. The business had revenue of $793.90 million during the quarter, compared to analyst estimates of $808.93 million. Mallinckrodt had a net margin of 11.43% and a return on equity of 14.79%. The business’s revenue was down 10.5% on a year-over-year basis. During the same period last year, the business earned $2.04 EPS. equities analysts anticipate that Mallinckrodt PLC will post 7.2 earnings per share for the current year.
In other news, VP Steven J. Romano purchased 2,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was acquired at an average cost of $21.96 per share, with a total value of $43,920.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, General Counsel Michael-Bryant Hicks purchased 7,900 shares of the stock in a transaction that occurred on Thursday, November 9th. The shares were purchased at an average cost of $20.80 per share, with a total value of $164,320.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 30,460 shares of company stock valued at $659,486. Company insiders own 0.77% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://ledgergazette.com/2018/01/19/fox-run-management-l-l-c-takes-position-in-mallinckrodt-plc-mnk.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.